Últimas noticias sobre Corvus Pharma (NASDAQ:CRVS) Bolsa

Corvus Pharma

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharmaceuticals Inc

WIIM

CRVS

Corvus Pharmaceuticals shares are trading higher. The company reported Q3 financial results.

Oppenheimer analyst Jeff Jones maintains Corvus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) with a Outperform and raises the price target from $8 to $14.

News

Price Target

Analyst Ratings

Oppenheimer Maintains Outperform on Corvus Pharma, Raises Price Target to $14

Earnings

Earnings Misses

Corvus Pharma Q3 2024 GAAP EPS $(0.60) Misses $(0.11) Estimate

ABOS

ABSI

ACNT

ACTG

AENT

AGEN

AIOT

AIRG

ALIT

ALTG

AMBC

AMPS

AMTX

APEI

AREB

ARIS

ARMN

ATRA

AUTL

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXSM

AZTA

BHIL

BLDE

BLFS

BLTE

The Beachbody Company, Inc. Class A Common Stock

BODI

BRTX

BTMD

BTTR

BWAY

BXSL

BZFD

CAMT

CART

CATX

CAVA

CBAT

CBLL

CCLD

CGEN

CHGG

CHMI

CLSD

CNNE

CRNX

CRON

CRWS

CVAC

CXAI

DAVA

DAVE

DRCT

DYAI

EARN

EGAN

ELMD

ETON

EVCM

EVGO

EYEN

FENG

FGEN

FIHL

FLNG

FOUR

FTCI

GENI

GENK

GMGI

GOVX

GRAL

GRDN

GROV

GRPN

GRVY

Earnings Scheduled For November 12, 2024

Corvus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) is set to give its latest quarterly earnings report on Tuesday, 2024-11-12. Here's what investors need to know before the announcement.
Analysts estimate that Corvus Pharma will report an earnings per share (EPS) of $-0.10. 
The announcement from Corvus Pharma is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Overview of Past Earnings</h3>
In the previous earnings release, the company beat EPS by $0.05, leading to a 9.67% increase in the share price the following trading session.
Here's a look at Corvus Pharma's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.12</td>
<td>-0.11</td>
<td>-0.12</td>
<td>-0.12</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.07</td>
<td>-0.12</td>
<td>-0.14</td>
<td>-0.12</td>
</tr>
<tr>
<td>Price Change %</td>
<td>10.0%</td>
<td>-12.0%</td>
<td>-6.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731333685_0.png" alt="eps graph" />
<h3>Corvus Pharma Share Price Analysis</h3>
Shares of Corvus Pharma were trading at $9.45 as of November 08. Over the last 52-week period, shares are up 538.51%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/CRVS/earnings">To track all earnings releases for Corvus Pharma visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

An Overview of Corvus Pharma's Earnings

The researchers created a murine model that confirmed that SPP1+ macrophages were associated with suppressed immunity to prostate cancer and shortened overall survival. Further analysis of the related genetic pathways revealed involvement of adenosine signaling through the adenosine 2A receptor. The researchers utilized ciforadenant to inhibit adenosine signaling in this model and the key findings demonstrating its potential to overcome this resistance to immunotherapy include:
<ul>
<li>Ciforadenant treatment associated with reduced immunosuppression and enhanced sensitivity to anti-PD1 therapy in the model&nbsp;</li>
<li>Ciforadenant treatment associated with reduced SPP1+ macrophage infiltration in the tumors, supporting a shift to a less immunosuppressive myeloid environment</li>
<li>The Adenosine Gene Signature, a biomarker that reflects adenosine induced immunosuppression in the tumor, was elevated in SPP1+ macrophages</li>
<li>Results from the model were consistent with data from the Phase 1b/2 clinical trial of ciforadenant in patients with mCRPC, which included data from 35 patients with advanced mCRPC, including 11 who received ciforadenant as a monotherapy (100 mg twice daily) and 24 that received ciforadenant (100 mg twice daily) in combination with atezolizumab (840 mg delivered intravenously every two weeks).&nbsp;5 of 24 (21%) receiving combination therapy had PSA partial responses defined as PSA reductions &gt;30%, compared to 1 of 11 (9%) receiving monotherapy</li>
</ul>

Reported Saturday, Corvus Pharmaceuticals Presents New Data Showing Ciforadenant's Potential To Overcome Immunotherapy Resistance In Advanced Prostate Cancer

U.S. stock futures were slightly lower this morning, with the Nasdaq futures falling around 0.1% on Monday.
Shares of Stellantis N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) fell sharply in today's pre-market trading after the company <a href="https://www.benzinga.com/quote/STLA/news">updated its 2024 guidance.</a>
Stellantis said it now expects FY24 operating margin of 5.5%-7.0%, down from its prior double-digit growth expectations.
Stellantis shares dipped 11.6% to $14.20 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Bitdeer Technologies Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) shares dipped 13% to $7.34 in pre-market trading after gaining over 5% on Friday.</li>
<li>Corvus Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) declined 11.6% to $4.55 in today's pre-market trading.</li>
<li>Venus Concept Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares declined 10.4% to $0.62 in pre-market trading. Venus Concept shares jumped around 20% on Friday after the company announced a $15 million debt-to-equity exchange transaction.</li>
<li>Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) shares fell 8.3% to $7.51 in pre-market trading.</li>
<li>Cipher Mining Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIFR#NASDAQ">CIFR</a>) shares fell 6.1% to $3.86 in pre-market trading. Northland Capital Markets, last week, initiated coverage on the stock with an Outperform rating and announced a $6 price target.</li>
<li>MicroStrategy Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) shares declined 6.1% to $165.51 in pre-market trading amid a decline in Bitcoin prices.</li>
<li>Hut 8 Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) shares fell 5.2% to $12.40 in pre-market trading amid a decline in Bitcoin prices.</li>
<li>Bit Digital, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTBT#NASDAQ">BTBT</a>) shares slipped 5.2% to $3.45 in pre-market trading amid a decline in Bitcoin prices.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/41075978/top-4-materials-stocks-that-may-implode-in-q3">Top 4 Materials Stocks That May Implode In Q3</a></li>
</ul>

Pre-Market Outlook

Markets

Movers

Trading Ideas

APLD

BTBT

BTDR

CIFR

MSTR

STLA

VERO

Stellantis, MicroStrategy, Bit Digital And Other Big Stocks Moving Lower In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Prime Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRME#NASDAQ">PRME</a>) stock moved upwards by 24.3% to $4.3 during Monday's pre-market session. The market value of their outstanding shares is at $516.1 million. </li>
<li>Traws Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRAW#NASDAQ">TRAW</a>) stock increased by 16.2% to $6.67. The company's market cap stands at $20.1 million. </li>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) shares increased by 14.28% to $2.8. The market value of their outstanding shares is at $3.2 million. </li>
<li>Addex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXN#NASDAQ">ADXN</a>) shares increased by 13.81% to $10.3. The market value of their outstanding shares is at $11.0 million. As per the news, the Q2 earnings report came out today. </li>
<li>BrainsWay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWAY#NASDAQ">BWAY</a>) stock increased by 13.01% to $9.12. The company's market cap stands at $152.1 million. </li>
<li>AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) shares rose 9.82% to $35.0. The market value of their outstanding shares is at $1.0 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares fell 20.8% to $0.23 during Monday's pre-market session. The company's market cap stands at $1.9 million. </li>
<li>Corvus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) shares declined by 11.66% to $4.55. The company's market cap stands at $284.6 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares decreased by 11.28% to $0.55. The company's market cap stands at $2.4 million. </li>
<li>Estrella Immunopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLA#NASDAQ">ESLA</a>) shares decreased by 10.93% to $1.06. The market value of their outstanding shares is at $38.5 million. As per the press release, Q4 earnings came out yesterday. </li>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) stock declined by 10.13% to $0.57. The company's market cap stands at $7.6 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares decreased by 7.5% to $0.66. The market value of their outstanding shares is at $4.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADXN

ANAB

BNOX

ENSC

ESLA

PRME

PTIX

THAR

TRAW

12 Health Care Stocks Moving In Monday's Pre-Market Session

Shares of NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) rose sharply in <a href="https://www.benzinga.com/markets/equities/24/09/41082193/teslas-chinese-rival-nio-snags-1-9b-investment-from-parent-strategic-investors-as-it-forays-into">today's pre-market.</a>
Nio announced Sunday that strategic investors, including Hefei Jianheng New Energy Automobile Investment Fund Partnership, Anhui Provincial Emerging Industry Investment Co., Ltd. and CS Capital Co., Ltd., have agreed to invest an aggregate of 3.3 billion yuan ($470.64 million) in cash in its subsidiary Nio China. Nio has concurrently agreed to invest 10 billion yuan (about $1.43 billion) in cash to subscribe to the newly issued shares of Nio China.
nIO shares jumped 12.7% to $7.35 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Zhongchao Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCMD#NASDAQ">ZCMD</a>) rose 54.6% to $2.04 in pre-market trading.</li>
<li>Fangdd Network Group Ltd.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUO#NASDAQ">DUO</a>) shares rose 50.8% to $1.90 in pre-market trading after jumping around 18% on Friday.</li>
<li>Kaixin Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KXIN#NASDAQ">KXIN</a>) gained 44.9% to $0.1303 in pre-market trading after dipping over 15% on Friday.</li>
<li>Garden Stage Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSIW#NASDAQ">GSIW</a>) rose 27.2% to $1.54 in pre-market trading after gaining around 3% on Friday.</li>
<li>Reliance Global Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELI#NASDAQ">RELI</a>) shares rose 27.2% to $2.79 in pre-market trading.</li>
<li>Future FinTech Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTFT#NASDAQ">FTFT</a>) gained 23.8% to $0.4670 in pre-market trading after declining around 4% on Friday.</li>
<li>MMTec, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTC#NASDAQ">MTC</a>) shares surged 21.3% to $0.4668 in pre-market trading after surging around 15% on Friday.</li>
<li>Uxin Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UXIN#NASDAQ">UXIN</a>) shares gained 20.8% to $6.28 in pre-market trading after jumping around 84% on Friday.</li>
<li>Dada Nexus Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DADA#NASDAQ">DADA</a>) shares jumped 15% to $2.08 in pre-market trading after surging 13% on Friday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Ensysce Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares dipped 24.7% to $0.2168 in pre-market trading after receiving a notice from the Nasdaq.</li>
<li>VS MEDIA Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSME#NASDAQ">VSME</a>) fell 20.4% to $0.78 in pre-market trading after dipping 19% on Friday.</li>
<li>Verb Technology Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERB#NASDAQ">VERB</a>) shares fell 18.1% to $0.0440 in pre-market trading after gaining over 5% on Friday.</li>
<li>CaliberCos Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWD#NASDAQ">CWD</a>) fell 14.7% to $0.5322 in pre-market trading.</li>
<li>Nano Labs Ltd&nbsp; (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NA#NASDAQ">NA</a>) declined 12.9% to $0.8795 in pre-market trading after jumping 74% on Friday.</li>
<li>Versus Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VS#NASDAQ">VS</a>) shares declined 12.4% to $1.06 in pre-market trading.</li>
<li>Stellantis N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) shares declined 11.6% to $14.20 in pre-market trading after the company updated its 2024 guidance. Stellantis said it now expects FY24 operating margin of 5.5%-7.0%, down from its prior double-digit growth expectations.</li>
<li>Corvus Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) fell 11.6% to $4.55 in today's pre-market trading.</li>
<li>Venus Concept Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares fell 10.4% to $0.62 in pre-market trading. Venus Concept shares jumped around 20% on Friday after the company announced a $15 million debt-to-equity exchange transaction.</li>
<li>Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) shares fell 8.3% to $7.51 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/41075978/top-4-materials-stocks-that-may-implode-in-q3">Top 4 Materials Stocks That May Implode In Q3</a></li>
</ul>

DADA

FTFT

GSIW

KXIN

RELI

UXIN

VERB

VSME

ZCMD

Why Nio Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket

U.S. stock futures were higher this morning, with the Dow futures gaining around 50 points on Wednesday.
Shares of Casella Waste Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWST#NASDAQ">CWST</a>) fell sharply in today's pre-market trading after the company announced a proposed public offering of <a href="https://widgets.benzinga.com/quote/CWST/news">Class A common stock</a>.
Casella Waste Systems shares fell 3.3% to $103.21 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>XCHG Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCH#NASDAQ">XCH</a>) shares dipped 15.3% to $9.40 in pre-market trading after gaining 34% on Tuesday.</li>
<li>SES AI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SES#NYSE">SES</a>) shares fell 6% to $0.9220 in pre-market trading. SES AI, on Tuesday, announced a collaboration with NVIDIA, Crusoe and Supermicro on AI for scientific initiative to accelerate material discovery in electric transportation.</li>
<li>Newegg Commerce, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEGG#NASDAQ">NEGG</a>) shares declined 4% to $0.83 in pre-market trading after jumping around 15% on Tuesday.</li>
<li>Corvus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) shares fell 3.6% to $5.30 in pre-market trading after declining 5% on Tuesday. Ladenburg, on Monday, maintained a Buy rating on the stock and raised its price target from $12 to $21.</li>
<li>Medical Properties Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPW#NYSE">MPW</a>) shares fell 3.2% to $6.04 in pre-market trading.</li>
<li>Harmony Gold Mining Company Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMY#NYSE">HMY</a>) shares fell 2.9% to $9.79 in pre-market trading.</li>
<li>Sana Biotechnology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>) shares declined 2.6% to $4.19 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/09/40898216/cramer-hewlett-packard-is-a-very-inexpensive-stock-likes-this-big-tech-stock">Cramer: Hewlett Packard Is A &#8216;Very Inexpensive&#8217; Stock, Likes This Big Tech Stock</a></li>
</ul>

CWST

NEGG

SANA

Casella Waste Systems, SES AI And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Corvus Pharmaceuticals shares are trading higher after Ladenburg maintained a Buy rating on the stock and raised its price target from $12 to $21.

Ladenburg Thalmann analyst Aydin Huseynov maintains Corvus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) with a Buy and raises the price target from $12 to $21.

Ladenburg Thalmann Maintains Buy on Corvus Pharma, Raises Price Target to $21

U.S. stocks were mixed, with the Dow Jones index gaining around 200 points on Monday.
Shares of Alcoa Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AA#NYSE">AA</a>) rose sharply during Monday's session after the company agreed to sell its 25.1% joint venture stake in Ma&#8217;aden for $1.1 billion, including $950 million <a href="https://www.benzinga.com/markets/equities/24/09/40873786/alcoa-pockets-1-1b-from-saudi-joint-venture-sale-details">in Ma&#8217;aden shares.</a>
Alcoa shares jumped 6.5% to $34.63 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Ascendis Pharma A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) shares jumped 19.8% to $142.76 after the company announced topline data from its pivotal approach trial of Transcon CNP (Navepegritide).</li>
<li>Bausch + Lomb Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLCO#NASDAQ">BLCO</a>) shares gained 15% to $17.86. Needham reiterated a Hold rating on Bausch &amp; Lomb.</li>
<li>Nuvalent, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUVL#NASDAQ">NUVL</a>) climbed 12.8% to $98.70 after the company highlighted results for its ROS1 and ALK-Positive NSCLC programs and accelerated its development timeline. Also, the company announced a $350 million public offering and multiple firms raised their respective price targets on the stock.</li>
<li>Fitell Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEL#NASDAQ">FTEL</a>) gained 12.5% to $17.75.</li>
<li>JBDI Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBDI#NASDAQ">JBDI</a>) jumped 11.1% to $29.38.</li>
<li>Lattice Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) surged 10.3% to $49.46. Lattice Semiconductor appointed Ford Tamer as CEO, effective immediately.</li>
<li>EchoStar Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SATS#NASDAQ">SATS</a>) rose 8.4% to $26.33. Morgan Stanley, on Friday, raised its price target on the stock from $14 to $20.</li>
<li>Stratasys Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSYS#NASDAQ">SSYS</a>) rose 7.9% to $7.61 after the company authorized a share repurchase program of up to $50 million.</li>
<li>Corvus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) gained 7.5% to $5.48. The announced it initiated the registrational Phase 3 clinical trial of Soquelitinib for patients with relapsed or refractory peripheral T-cell lymphoma.</li>
<li>Viasat, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSAT#NASDAQ">VSAT</a>) rose 6.3% to $13.57.</li>
<li>Hertz Global Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NASDAQ">HTZ</a>) rose 5.5% to $3.1650.</li>
<li>Sprouts Farmers Market, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NASDAQ">SFM</a>) gained 4.2% to $106.42. Evercore ISI Group analyst Michael Morris upgraded Sprouts Farmers Market from In-Line to Outperform and raised the price target from $96 to $120.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/24/09/40876800/this-analyst-with-86-accuracy-rate-sees-around-9-upside-in-rh-here-are-5-stock-picks-for-last-week-f"> </a>
<ul>
<li><a href="https://www.benzinga.com/24/09/40876800/this-analyst-with-86-accuracy-rate-sees-around-9-upside-in-rh-here-are-5-stock-picks-for-last-week-f">This Analyst With 86% Accuracy Rate Sees Around 9% Upside In RH &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Intraday Update

ASND

BLCO

FTEL

JBDI

LSCC

NUVL

SATS

SSYS

VSAT

Alcoa, Lattice Semiconductor, Stratasys And Other Big Stocks Moving Higher On Monday

Corvus Pharmaceuticals shares are trading higher after the company announced it initiated the registrational Phase 3 clinical trial of Soquelitinib for patients with relapsed or refractory peripheral T-cell lymphoma.

Soquelitinib is a potential first-in-class ITK inhibitor with broad potential in cancer and immune diseases &nbsp;
There are currently no fully approved agents for the treatment of relapsed PTCL and soquelitinib has been granted Orphan Drug Designation and Fast Track Designation by the FDA
BURLINGAME, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>), a clinical-stage biopharmaceutical company, today announced that it has initiated a registrational Phase 3 clinical trial of soquelitinib for patients with relapsed/refractory peripheral T-cell lymphoma (PTCL). The clinical trial is a randomized, controlled study that will evaluate the efficacy and safety of soquelitinib compared to standard of care chemotherapy.

Biotech

General

Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial Of Soquelitinib For Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

Corvus Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 EPS results.

Shares of Fortinet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>) rose sharply in today's pre-market trading after the company reported better-than-expected second-quarter financial results and<a href="https://www.benzinga.com/news/earnings/24/08/40203474/fortinet-q2-earnings-revenue-beat-eps-beat-strong-guidance-and-more"> issued guidance above estimates.</a>
Fortinet's second-quarter revenue increased 11% year-over-year to $1.43 billion, beating consensus estimates of $1.403 billion. The cybersecurity company reported second-quarter adjusted earnings of 57 cents per share, beating analyst estimates of 41 cents per share.
Fortinet shares jumped 17% to $65.29 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Richtech Robotics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RR#NASDAQ">RR</a>) rose 68.1% to $0.6220 in today's pre-market trading after dipping around 74% on Tuesday.</li>
<li>Lumen Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) gained 43% to $7.15 in pre-market trading after the company reported better-than-expected second-quarter revenue results.</li>
<li>Zhongchao Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCMD#NASDAQ">ZCMD</a>) gained 34.2% to $1.65 in pre-market trading.</li>
<li>Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) jumped 24% to $29.60 in pre-market trading after the company reported better-than-expected second-quarter financial results and issued third-quarter revenue guidance above estimates.</li>
<li>Latham Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIM#NASDAQ">SWIM</a>) shares gained 20.6% to $3.75 in pre-market trading after the company reported better-than-expected second-quarter financial results and raised its FY24 revenue guidance above estimates. Additionally, the company announced an acquisition of Coverstar Central.</li>
<li>Mynd.ai, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYND#NYSE">MYND</a>) shares rose 15.9% to $2.55 in pre-market trading after falling around 7% on Tuesday.</li>
<li>Beyond Air, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) shares rose 14.3% to $0.5770 in pre-market trading after the company reported better-than-expected quarterly EPS results.</li>
<li>Snow Lake Resources Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITM#NASDAQ">LITM</a>) gained 12.8% to $0.5756 in pre-market trading after jumping around 13% on Tuesday.</li>
<li>Corvus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) shares gained 10% to $3.30 in pre-market trading after the company reported a narrower-than-expected quarterly loss.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Scorpius Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCPX#NYSE">SCPX</a>) shares dipped 77% to $1.30 in pre-market trading after gaining 19% on Tuesday. Scorpius announced that it has surpassed $100 million in near-term business development opportunities across government and commercial sectors.</li>
<li>Talis Biomedical Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLIS#NASDAQ">TLIS</a>) shares declined 52.7% to $4.25 in pre-market trading after the company initiated a board restructuring.</li>
<li>Porch Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCH#NASDAQ">PRCH</a>) declined 38.2% to $1.07 in pre-market trading after reporting weak quarterly results.</li>
<li>Stem, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) shares declined 37.1% to $0.6274 in pre-market trading after the company reported mixed second-quarter financial results.</li>
<li>Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) shares fell 36.2% to $6.27 in pre-market trading after posting a loss for the second quarter.</li>
<li>DZS Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DZSI#NASDAQ">DZSI</a>) fell 36.2% to $0.66 pre-market trading after the company announced it received a delisting notice from the Nasdaq.</li>
<li>VBI Vaccines Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VBIV#NASDAQ">VBIV</a>) fell 32.2% to $0.09 in today's pre-market trading after jumping 111% on Tuesday.</li>
<li>Nevro Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) shares fell 31.1% to $5.99 in pre-market trading after the company reported worse-than-expected second-quarter sales results.</li>
<li>Evotec SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) fell 24.5% to $2.90 in pre-market trading after declining around 11% on Tuesday.</li>
<li>Cryoport, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) shares fell 23.5% to $5.95 in pre-market trading after posting weak quarterly sales.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40194186/top-4-materials-stocks-which-could-rescue-your-portfolio-this-month">Top 4 Materials Stocks Which Could Rescue Your Portfolio This Month</a></li>
</ul>

CYRX

DZSI

FTNT

LITM

LUMN

MYND

NVRO

PRCH

SCPX

STEM

SWIM

TLIS

UPST

VBIV

XAIR

Why Fortinet Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket

Corvus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.12) by 41.67 percent. This is a 50 percent increase over losses of $(0.14) per share from the same period last year.

Earnings Beats

Corvus Pharma Q2 EPS $(0.07) Beats $(0.12) Estimate

Corvus Pharmaceuticals Announces FDA Fast Track Designation For Soquelitinib In Treatment Of Relapsed Or Refractory PTCL; Phase 3 Clinical Trial To Begin Initial Enrollment In Q3 2024

Corvus Pharmaceuticals Announces Publication In Science Signaling Demonstrating ITK Inhibition By Soquelitinib Induces Anti-Inflammatory Treg Cells; Study Highlights Potential For Treating Inflammatory Autoimmune And Allergic Diseases

Corvus stock climbs 7% following Mizuho upgrade

Pre-earnings options volume in Corvus Pharmaceuticals (CRVS) is normal with calls leading puts 8:5. Implied volatility suggests the market is antic...

Corvus Pharmaceuticals options imply 12.0% move in share price post-earnings

Pre-earnings options volume in Corvus Pharmaceuticals (CRVS) is 1.3x normal with puts leading calls 8:5. Implied volatility suggests the market is ...

Corvus Pharmaceuticals options imply 17.7% move in share price post-earnings

Corvus Pharmaceuticals GAAP EPS of -$0.60 misses by $0.48

Corvus Pharmaceuticals, Inc. (CRVS) Q3 2024 Earnings Call Transcript

Oppenheimer analyst Jeff Jones raised the firm's price target on Corvus Pharmaceuticals (CRVS) to $14 from $8 and keeps an Outperform rating on the...

Corvus Pharmaceuticals price target raised to $14 from $8 at Oppenheimer

Corvus Pharmaceuticals: The Market Likes The Story

Jefferies raised the firm's price target on Corvus Pharmaceuticals (CRVS) to $13 from $8 and keeps a Buy rating on the shares ahead of the report o...

Corvus Pharmaceuticals price target raised to $13 from $8 at Jefferies

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on CRVS stock, giving a Buy rating yesterday. Graig Suvannavejh's r...

Corvus Pharmaceuticals' Soquelitinib: Optimism and Market Potential Drive Buy Rating

Corvus Pharmaceuticals (CRVS) announced new preclinical data highlighting the potential of soquelitinib, the Company's lead ITK inhibitor program, ...

Corvus Pharmaceuticals announces preclinical dataon soquelitinib

Press Releases

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2024 Financial Results on August 6, 2024

Health Care

Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Comments

Corvus Pharma

Noticias

Últimas noticias sobre Corvus Pharma (NASDAQ:CRVS) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL